Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P200031/S011

Organ Care System (OCS) Liver

TransMedics, Inc. · Decision date Oct 22, 2025

FDA DECISIONP200031/S011

What did the FDA decide?

FDA records P200031/S011 as a supplement to PMA P200031, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 22, 2025.

FDA approval order statement

Changes in assembly inspection documentation
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Oct 22, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P200031/S011
Regulatory pathway
PMA supplement
Product code
QQK
Decision code
OK30
Decision date
Oct 22, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Normothermic machine perfusion system for the preservation of donor livers prior to transplantation.

Product code
QQK
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P200031/S011 received

    Application receipt date recorded by FDA.

  2. P200031/S011 · FDA decision

    30-Day Notice

  3. P200031/S012 · Related supplement

    Organ Care System (OCS) Liver

  4. P200031/S014 · Related supplement

    Organ Care System (OCS) Liver

  5. P200031/S013 · Related supplement

    Organ Care System (OCS) Liver

Timeline entries are records held by MedtechLedger for P200031. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P200031

Product / regulatory recordCompanyPathwayDecision dateSource
TransMedics, Inc.PMA supplementDec 16, 2025FDA
TransMedics, Inc.PMA supplementMar 9, 2026FDA
TransMedics, Inc.PMA supplementMay 13, 2026FDA

Explore the linked device profile

Other records with product code QQK

Product / regulatory recordCompanyPathwayDecision dateSource
Organox LimitedPMA supplementOct 9, 2026FDA
Organox LimitedPMA supplementAug 7, 2026FDA
Organox LimitedPMA supplementJul 8, 2026FDA
Organox LimitedPMA supplementJul 7, 2026FDA
Organox LimitedPMA supplementJun 5, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

TransMedics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
200 Minuteman Rd., Suite 302, Andover, MA, 01810

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records